Skip to main content

ATOS

Stock
Health Care
Biotechnology

Performance overview

ATOS Price
Price Chart

Forward-looking statistics

Beta
0.83
Risk
61.86%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Company info

SectorHealth Care
IndustryBiotechnology
Employees10
Market cap$157.2M

Fundamentals

Enterprise value$42.1M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.20
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$967K
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth+2.3
Credit-10.9
Liquidity+1.5
Inflation+2.1
Commodities+1.2
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio-3.14
Price to sales
P/E Ratio-3.14
Enterprise Value to Revenue
Price to book1.68

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Investment Research (May 15, 2025)
Atossa To Conduct Endoxifen Mid-Stage Study In Sweden

Atossa Therapeutics Inc (NASDAQ: ATOS) has received approval from the Swedish Ethics Review Authority to begin a Phase 2 clinical study of oral Endoxifen to reduce mammographic breast density (MBD).  Atossa plans to start enrolling participants in Q4 of 2021.

Benzinga (September 2, 2021)
A tiny biotech company focused on breast cancer treatments has soared 29% amid Reddit hype

Retail traders hyped Atossa Therapeutics on Reddit's penny stocks thread, saying it's on track to rocket.

Business Insider (June 22, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free